AACR 2023 | Optimizing and overcoming resistance to current KRAS inhibitors

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the latest developments in KRAS inhibitors. Further research is needed to find patients who will benefit more from KRAS inhibitors, as well as the best combination strategies, where further downstream inhibition has been found to be promising. Dr Schram additionally highlights strategies to overcome resistance to first generation KRAS inhibitors. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.